Research programme: anti-VPAC antibody therapeutics - Oxurion

Drug Profile

Research programme: anti-VPAC antibody therapeutics - Oxurion

Alternative Names: Anti-VPAC1 antibody

Latest Information Update: 11 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Leuven
  • Developer Oxurion
  • Class Monoclonal antibodies
  • Mechanism of Action Pituitary-adenylate-cyclase-activating-polypeptide-type I-receptor-antagonists; Vasoactive intestinal polypeptide antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Thrombocytopenia

Most Recent Events

  • 10 Sep 2018 Thrombogenics is now called Oxurion
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Thrombocytopenia in Europe (Parenteral)
  • 14 Nov 2007 Thrombogenics has selected an anti-VPAC antibody candidate for the treatment of thrombocytopenia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top